SANOCHEMIA Pharmazeutika AG: Sanochemia - Tolperisone USA: Start of clinical phase-I trial

Wien (pta016/11.09.2017/10:00 UTC+2) Vienna, 11. September 2017 - Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307 ISIN DE000A1G7JQ9), announces the start of a Phase I trial sponsored by its partner Neurana Pharmaceuticals Inc. (Neurana). The aim of the clinical study is to confirm the non-sedative properties of tolperisone.

This study is designed as a three-way cross-over study utilizing tolperisone, cyclobenzaprine and placebo. Cyclobenzaprin is the market-share leader in the skeletal muscle relaxant market, which represents more than 60 million prescriptions per year.

Sanochemia's Partner Neurana anticipates having topline results from the study in late third quarter 2017.

"We are excited that the Phase I study has been started successfully. The results of the study will confirm the non-sedating side effects of tolperisone, which clearly differentiates tolperisone from other muscle relaxants." Dr. Christina Abrahamsberg, CSO Sanochemia Pharmazeutika AG.

Jeff Raser, CEO Neurana Pharmaceuticals Inc. "We believe that tolperisone hast he potential to provide millions of patients with relief from neuromuscular spasms without sedation, which is a problem with other products in this category."

About Neurana Pharmaceuticals Inc.
Neurana Pharmaceutical Inc. is a privately held company based in San Diego, CA and the exclusive licensee for Tolperisone in North America and other territories from Sanochemia Pharmazeutika AG. The licensing agreement provides Neurana the right to develop and market Sanochemia's proprietary and patent protected Tolperisone formulation in the United States and other licensed territories. Neurana plans to initially develop Tolperisone for the treatment of acute, painful muscle spasms as well as for spasticity.
--------------------------------------------------------------------------------------------------------------------------
About Tolperisone
Tolperisone is a muscle relaxant used for the symptomatic treatment of spasticity. Tolperisone holds a market-leading position in Eastern Europe, Germany and parts of Asia for the treatment of muscle pain and neuromuscular spasms. Tolperisone shows a unique, double action mechanism that acts on the peripheral neural system as well as on the spinal cord and brain stem to alleviate severe muscle cramps and significantly improve patient mobility. Tolperisone, unlike other marketed muscle relaxant products, has no sedative side effects.

(end)

Emitter:	SANOCHEMIA Pharmazeutika AG Boltzmanngasse 11 1090 Wien Austria
Contact Person:	Bettina Zuccato
Phone:	+43 1 3191456-336
E-Mail:	b.zuccato@sanochemia.at
Website:	www.sanochemia.at
ISIN(s):	AT0000776307 (Share) DE000A1G7JQ9 (Bond)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart; Vienna Stock Exchange (mid Market)